Clinical Trials Logo

Clinical Trial Summary

Alzheimer's/dementia is an increasingly critical public health risk, with over 50 million Americans at risk for the disease. To stem the burden of Alzheimer's disease, prophylactic and protective strategies such as physical activity and sleep have been recommended to reduce the risk of cognitive decline and Alzheimer's/dementia. Previous research indicate that exercise improves cognition and lowers dementia risk and may be a promising intervention to address dementia risk in the general population. Sleep, specifically slow wave sleep, may reduce dementia risk, based on previous work showing that greater levels of slow wave sleep was related to higher cognition. However, little is known about the independent and combined effects exercise and sleep have on cognition. The proposed study therefore aims to investigate the independent and combined effects exercise (aerobic and stretching) and sleep have on cognition and what heart health, sleep and stress correlates confound this association.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04855630
Study type Interventional
Source NYU Langone Health
Contact Azizi A Seixas, PhD
Phone 646-501-3430
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date May 1, 2021
Completion date November 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Active, not recruiting NCT03430648 - Is Tau Protein Linked to Mobility Function?
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Recruiting NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Not yet recruiting NCT03208491 - [email protected]: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders N/A
Withdrawn NCT02707978 - F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) Phase 2
Recruiting NCT04381468 - SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) Phase 1/Phase 2
Recruiting NCT04604600 - Multimodal Biomarkers for Diagnosis and Prognosis in VCI Phase 3
Recruiting NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT04488419 - ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease Phase 2
Completed NCT04571697 - A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
Recruiting NCT03671889 - ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease N/A
Recruiting NCT03056495 - Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease Phase 1
Recruiting NCT03991624 - Lack of Decision-making in Patients With Alzheimer's Disease : Functions Involved and the Daily Consequences N/A